The historical rank and industry rank for Nuvation Bio's Gross Margin % or its related term are showing as below:
NUVB'
s Gross Margin % Range Over the Past 10 Years
Min: 10.1 Med: 10.1 Max: 10.1
Current: 10.1
During the past 5 years, the highestGross Margin % of Nuvation Bio was 10.10%. The lowest was 10.10%. And the median was 10.10%.
NUVB's Gross Margin % is ranked worse than 88.95% of 742
companies
in the Biotechnology industry
Industry Median: 60.055
vs NUVB: 10.10
Nuvation Bio had a gross margin of 26.18% for the quarter that ended in Dec. 2024 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Nuvation Bio was 0.00% per year.
Nuvation Bio Gross Margin % Historical Data
The historical data trend for Nuvation Bio's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nuvation Bio's Gross Margin %
For the Biotechnology subindustry, Nuvation Bio's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuvation Bio's Gross Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuvation Bio's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Nuvation Bio's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Nuvation Bio (NYSE:NUVB) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Nuvation Bio had a gross margin of 26.18% for the quarter that ended in Dec. 2024 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Nuvation Bio Gross Margin % Related Terms
Thank you for viewing the detailed overview of Nuvation Bio's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NUVB has been successfully added to your 